Menu

Home / For Visitors / 2022 Exhibitor Product / ALA-3000, a 1-month Ketamine released Injectable for treatment-resistant depression

ALA-3000, a 1-month Ketamine released Injectable for treatment-resistant depression

Category: Pharmaceutical

Exhibitor: ALAR PHARMACEUTICALS INC.

Booth No: S610

Characteristic

ALA-3000, a monthly release injectable of Ketamine, indicating for treatment-resistant depression (TRD). Through the controlled release formulation, it is anticipated that the steady pharmacokinetic profile would reduce the risks of adverse events resulting from ketamine (e.g. dissociation, sedation, and perceptual changes) and improve patient compliance. The pre-IND meeting deems the development through 505(b)(2) regulatory pathway. The IND-enabling studies are ongoing.

Other Products

Products you may be interested in

Highest Rated Products

TOP